The Role of Adjuvant Corneal Cross-linking in the Management of Infectious Keratitis: An OCT-Based Assessment Study.
Adv TherJun 6, 2026 (epub)
Shady Soliman, Dalia Said, Sundas Maqsood et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the impact of adjuvant corneal cross-linking (CXL) in 40 patients with infectious keratitis. While CXL did not significantly alter healing duration or final visual outcomes, it was associated with a statistically significant reduction in scar thickness post-healing (p < 0.03).
Key findings
- Mean healing duration was 27.3 ± 9.27 days in the medical treatment group and 30.75 ± 7.39 days in the CXL group.
- AS-OCT parameters showed significant reduction compared to preoperative state, with no significant difference between groups (p > 0.05).
- Scar thickness post-healing was significantly reduced in the CXL group compared to the medical treatment group (p < 0.03).
Why it matters
Understanding the role of adjuvant therapies like CXL in infectious keratitis can help clinicians optimize treatment strategies, particularly in managing scar formation and long-term visual outcomes.